PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.02%
Positive revenue growth while 3391.T is negative. John Neff might see a notable competitive edge here.
7.85%
Positive gross profit growth while 3391.T is negative. John Neff would see a clear operational edge over the competitor.
14.12%
EBIT growth similar to 3391.T's 13.77%. Walter Schloss might infer both firms share similar operational efficiencies.
30.87%
Operating income growth above 1.5x 3391.T's 10.11%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
8.00%
Net income growth under 50% of 3391.T's 27.65%. Michael Burry would suspect the firm is falling well behind a key competitor.
8.01%
EPS growth under 50% of 3391.T's 27.53%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
8.01%
Diluted EPS growth under 50% of 3391.T's 29.19%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.00%
Share reduction while 3391.T is at 0.11%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.61%
10Y CAGR of 1.61% while 3391.T is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
1.61%
5Y revenue/share CAGR under 50% of 3391.T's 54.09%. Michael Burry would suspect a significant competitive gap or product weakness.
-23.57%
Negative 3Y CAGR while 3391.T stands at 32.87%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Negative 10Y OCF/share CAGR while 3391.T stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-100.00%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
No Data
No Data available this quarter, please select a different quarter.
0.22%
10Y net income/share CAGR of 0.22% while 3391.T is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
0.22%
Below 50% of 3391.T's 123.48%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-39.53%
Negative 3Y CAGR while 3391.T is 25.31%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.39%
Negative 3Y equity/share growth while 3391.T is at 45.80%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-100.00%
Cut dividends over 10 years while 3391.T stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-100.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
No Data
No Data available this quarter, please select a different quarter.
-99.58%
Firm’s AR is declining while 3391.T shows 4.34%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.78%
Inventory is declining while 3391.T stands at 1.36%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
6.99%
Asset growth above 1.5x 3391.T's 0.46%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.08%
BV/share growth above 1.5x 3391.T's 0.09%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
10.80%
We have some new debt while 3391.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
63.10%
We expand SG&A while 3391.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.